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Background
The need of rescue antiretroviral regimens is progres-
sively increasing, due to the unavoidable long-term
emerging of multiresistant HIV strains.
Methods
An open-label study featuring the administration of the
fusion inhibitor enfuvirtide (T-20) as a part of salvage
anti-HIV regimens in a cohort of hardly pre-treated and
multiresistant patients (p) with advanced HIV disease, fol-
lowed until at least three consecutive years, is presented.
Results
The efficacy and safety parameters of enfuvirtide adjunct
to an optimized background were assessed monthly in 21
severely compromised p, with a baseline viremia ranging
from 64,000 to over 500,000 HIV-RNA copies/mL, and a
CD4+ lymphocyte count ranging from 11 to 213 cells/μL.
At the time of enfuvirtide introduction, the background
antiretroviral therapy was modified according to both gen-
otypic-virtual phenotypic resistance assays, but only 15 of
21 p could rely on at least one in vitro effective drug (dur-
ing the first years of our experience, raltegravir, maraviroc,
etravirine, riplpivirine, and also tipranavir and darunavir
were not still available). Anyway, a rapid and significant
drop of viremia (at least one Log10 HIV-RNA copies/mL),
associated with a 30-280% increase of CD4+ cell count
versus baseline values was observed in all p, although 13
our of 15 p who could rely on an optimized background
had a sustained response (12-36 months). In 11 p, a sur-
prising dissociation between a favorable virological
response and a progressive loss of CD4+ cells was
observed. Although frequent, local injection site adverse
effects never represented the major cause of enfuvirtide
interruption.
Discussion
Expectations and concerns on the use of enfuvirtide as a
novel anti-HIV compound in daily practice are still
debated, since no specific recommendations have been
produced (especially with regard with the novel, available
compounds), when excluding the assumption that enfuvir-
tide appears significantly more effective when administered
concurrently with at least 1-2 other active antiretrovirals,
although the reported experiences often included p on very
advanced salvage therapies. The management of the fre-
quent site injection reactions represents an adjunctive con-
cern for these multi-problematic HIV-infected p.
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